- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05599282
The Efficacy and Safety of an Amino Acid Supplement in Adults
A 90-day, Double-blind, Placebo-controlled, Randomized, Parallel-Group Efficacy and Safety Study of an Amino Acid Supplement in Adults
The primary objective of this clinical trial is to determine the efficacy of once daily oral AAS use, as compared to placebo, in increasing serum IGF-1 concentrations within adults aged 35-75 years for up to 90 days. Additionally, the safety and tolerability of the AAS, as compared to placebo, will be measured by the occurrence of and/or changes in treatment-emergent adverse events (AEs).
For the study population, the eligibility criteria limit the presence of confounding variables that could influence study outcomes. Participants will be men and women between 35 and 75 years of age to account for the age range in which humans experience a decline in HGH/IGF-1. Each participant will be deemed eligible to participate by the Qualified Investigator (QI) by means of an extensive review of medical history, laboratory results, and physical examination. Participants will be required to have body mass index (BMI) measurements between 18.5 and 35.0 kg/m2 to ensure that their body weight/composition will not have a confounding effect on their HGH levels (18, 19) and to facilitate generalizability. Participants will be required to maintain current medication and supplements use and sleep throughout the study. They must also abstain from any over-the counter (OTC) medications and/or supplements that may affect the efficacy or safety of the AAS.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Ontario
-
London, Ontario, Canada, N6A5R8
- KGK Science Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Males and females between 35-75 years of age at baseline
- Weigh at least 52 kg for males and 45 kg for females
- BMI between 18.5-35.0 kg/m2, inclusive at screening
- Serum IGF-1 concentrations within ≤ 2 SDs of age-adjusted reference range as defined by the clinical laboratory
Individual is not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening
Or,
Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include:
- Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System)
- Double-barrier method
- Intrauterine devices
- Non-heterosexual lifestyle or agrees to use contraception if planning on changing to heterosexual partner(s)
- Vasectomy of partner at least 6 months prior to screening
- Provided voluntary, written, informed consent to participate in the study.
- Agrees to maintain current lifestyle habits throughout the study, including medications, supplements, and sleep.
- Agrees to avoid taking new supplements.
- Willingness to complete study assessments, journals, and all clinic visits
- Deemed eligible to participate as determined by medical history, laboratory results, and physical exam as assessed by QI
Exclusion Criteria:
- Individuals who are pregnant, breast feeding, or planning to become pregnant during the study
- Allergy, sensitivity, or intolerance to investigational product (IP) and/or placebo active or inactive ingredients
- Has a condition known to directly involve and/or affect IGF-1, including acromegaly, dwarfism, malnutrition, pituitary disorders, and Laron Syndrome
- Current or history of any significant diseases involving dementia (e.g., Alzheimer's disease, vascular dementia, etc.)
- Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable.
- Current diagnosis or history of chronic kidney disease (creatinine levels > 1.1 mg/dl for women; > 1.2 mg/dl for men)
- Current diagnosis or history of a thyroid-related disorder and/or disease
- Current diagnosis of liver diseases
- Current diagnosis of primary hypercholesterolemia (LDL-C 160-189 mg/dl [4.1-4.8 mmol/l]; non-HDL-C 190-219 mg/dl [4.9-5.6 mmol/l])
- Current diagnosis of primary hypertriglyceridemia (triglycerides >150 mg/dl, fasting)
- Current diagnosis of stage 2 hypertension (> 140/90 mmHg)
- Current diagnosis of type 1 or type 2 diabetes mellitus (HbA1c > 6.5%)
- History or presence of gastrointestinal (including prior bariatric bypass surgery), hepatic or renal disease, or any other condition that may interfere with the absorption, distribution, metabolism, or excretion of IPs, based on the opinion of the QI
- History of cardiovascular disease and/or significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis
- History (within past two years at screening) or presence of diagnosis of alcohol abuse, a substance abuse disorder, known drug dependence, or seeking treatment for alcohol or substance abuse related disorder.
- Current use of prescribed medications, over-the-counter (OTC) medications, or supplements which may affect the efficacy and/or safety of the IP
- Individuals who work or plan to work night shifts
- Individuals who have travelled to other time zones within two weeks prior to baseline or plan to travel to other time zones during the study
- Alcohol intake average of > 2 standard drinks per day as assessed by the QI
- Clinically significant abnormal laboratory results at screening as assessed by the QI
- Participation in other clinical research studies 30 days prior to enrollment will be assessed on a case-by-case basis by the QI
- Individuals who are unable to give informed consent
- Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Amino Acid Supplement
Participants will be instructed to take four (4) capsules of Amino Acid Supplement with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the Investigational Product (IP). The IP must be consistently consumed immediately before nighttime sleep throughout the study. If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the IP, that IP use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily. |
Four capsules of Amino Acid Supplement will be taken once a day for 90 days.
|
Placebo Comparator: Placebo
Participants will be instructed to take four (4) capsules of Placebo with a full glass of water daily for up to 90 days, starting on day 1. No substance other than water (i.e., food, drink other than water, and/or medication, supplement, vitamin, and/or mineral) can be consumed two hours before or after taking the placebo. The placebo must be consistently consumed immediately before nighttime sleep throughout the study. If a dose is missed participants are instructed to record the missed dose in their study journal. Missed doses will not be taken at a later time or date. If any substance other than water is consumed two hours before or after taking the placebo, that placebo use will be counted as a missed dose. Participants will be advised not to exceed four (4) capsules daily. |
Four capsules of Placebo will be taken once a day for 90 days.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The difference in serum IGF-1 concentrations from baseline up to 30 days of supplementation between Amino Acid Supplement (AAS) compared to placebo.
Time Frame: baseline (day 1) and 31 days
|
The difference in serum IGF-1 concentrations (ng/ml) from baseline (day 1) to 30 days (day 31) of supplementation between AAS will be compared to placebo
|
baseline (day 1) and 31 days
|
The difference in serum IGF-1 concentrations from baseline up to 60 days of supplementation between Amino Acid Supplement (AAS) compared to placebo.
Time Frame: baseline (day 1) and 61 days
|
The difference in serum IGF-1 concentrations (ng/ml) from baseline (day 1) up to 60 days (day 61) of supplementation between AAS will be compared to placebo
|
baseline (day 1) and 61 days
|
The difference in serum IGF-1 concentrations from baseline up to 90 days of supplementation between Amino Acid Supplement (AAS) compared to placebo.
Time Frame: baseline (day 1) and 91 days
|
The difference in serum IGF-1 concentrations (ng/ml) from baseline (day 1) up to 90 days (day 91) of supplementation between AAS will be compared to placebo
|
baseline (day 1) and 91 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Incidence of pre-emergent adverse events following 90 days of supplementation with Amino Acid Supplement (AAS) compared to placebo
Time Frame: 105 days
|
Incidence of pre-emergent adverse events following 90 days of supplementation with Amino Acid Supplement (AAS) will be compared to placebo.
A follow-up safety call will also be conducted 2 weeks after the 90 day treatment (day 105) with Amino Acid Supplement.
|
105 days
|
Incidence of post-emergent adverse events following 90 days of supplementation with Amino Acid Supplement (AAS) compared to placebo
Time Frame: 105 days
|
Incidence of post-emergent adverse events following 90 days of supplementation with Amino Acid Supplement (AAS) will be compared to placebo.
A follow-up safety call will also be conducted 2 weeks after the 90 day treatment (day 105) with Amino Acid Supplement.
|
105 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: David Crowley, MD, KGK Science Inc.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 21ZTCPS01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy
-
Prevent Age Resort "Pervaya Liniya"RecruitingHealthy Aging | Healthy Diet | Healthy LifestyleRussian Federation
-
Maastricht University Medical CenterCompletedHealthy Volunteers | Healthy Subjects | Healthy AdultsNetherlands
-
Yale UniversityNot yet recruitingHealth-related Benefits of Introducing Table Olives Into the Diet of Young Adults: Olives For HealthHealthy Diet | Healthy Lifestyle | Healthy Nutrition | CholesterolUnited States
-
Hasselt UniversityRecruitingHealthy | Healthy AgingBelgium
-
Galera Therapeutics, Inc.Syneos HealthCompleted
-
Galera Therapeutics, Inc.Syneos HealthCompletedHealthy | Healthy VolunteersAustralia
-
University of PennsylvaniaActive, not recruitingHealthy | Healthy AgingUnited States
-
Chalmers University of TechnologyGöteborg UniversityCompletedHealthy | Nutrition, HealthySweden
-
University of ManitobaNot yet recruitingHealthy | Healthy Diet
Clinical Trials on Amino Acid Supplement
-
Leeds Beckett UniversityNot yet recruitingRheumatoid Arthritis | Muscle Atrophy
-
Abbott NutritionCompleted
-
University of Alabama at BirminghamAbbott NutritionCompletedObesity | Post-gastric BypassUnited States
-
The University of Texas Health Science Center at...National Center for Advancing Translational Sciences (NCATS); IIMS-UT Health...Not yet recruiting
-
Wageningen UniversityRecruiting
-
University of Colorado, DenverCompletedObesity | Polycystic Ovarian Syndrome | Hepatic SteatosisUnited States
-
University of VermontCompletedExercise-induced Delayed Onset Muscle SorenessUnited States
-
Universitaire Ziekenhuizen KU LeuvenRecruiting
-
Pennington Biomedical Research CenterCompletedAging | Growth Hormone Treatment
-
University of North Carolina, Chapel HillNational Strength and Conditioning FoundationCompletedObesity | Cardiovascular Risk FactorUnited States